ARTICLE | Company News

Praecis cancer, autoimmune news

June 26, 2006 7:00 AM UTC

PRCS said that it will no longer seek to partner or out-license Plenaxis abarelix and that it hired Canaccord Adams to explore financing alternatives and other strategic options. Last year, PRCS stopped promoting the prostate cancer treatment in the U.S. due to lack of sales. The company continues to develop its PPI-2458 methionine aminopeptidase 2 (MetAP2) inhibitor, which is in Phase I testing to treat non-Hodgkin's lymphoma (NHL) and solid tumors. ...